This inventor holds 4 USPTO granted patents. Top assignees: Kaken Pharmaceutical Company, Ltd., Molecular Research Institute. Active years: 2005-2007.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 2005-2007
Title: **Tadashi Okuno: Innovator in Pharmaceutical Chemistry**
Introduction
Tadashi Okuno is a distinguished inventor based in Kyoto, Japan, renowned for his contributions to the field of pharmaceutical chemistry. With a total of four patents to his name, he has made significant advancements, particularly in compounds related to growth hormone releasing activity.
Latest Patents
Among his latest innovations are the patents for Amide derivatives and N-acylated lipophilic amino acid derivatives. Both patents describe compounds characterized by a structural formula where specific components, such as lipophilic groups and amino group variations, exhibit growth hormone releasing activity in humans and animals. These compounds also include pharmaceutically acceptable salts and individual isomers thereof, highlighting their potential in medical applications.
Career Highlights
Throughout his career, Tadashi Okuno has made substantial contributions while working for leading organizations such as Kaken Pharmaceutical Company, Ltd. and the Molecular Research Institute. His work has been pivotal in advancing pharmaceutical research and development, particularly in areas that focus on enhancing human health through innovative therapeutic solutions.
Collaborations
Tadashi has collaborated with notable professionals in his field, including Nobuo Ishiyama and Kiyoshi Inoguchi. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and the pursuit of groundbreaking discoveries in pharmaceutical innovations.
Conclusion
In summary, Tadashi Okuno's work exemplifies innovation and dedication to advancing pharmaceutical chemistry. His patents reflect significant potential in fostering therapeutic advancements, contributing to better health outcomes for individuals. As he continues his journey, his contributions are expected to leave a lasting impact on the industry.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile